Gilead’s Covid Drug Win Could Clog Pipeline for Other Treatments (1)

The future of Covid-19 treatment is cloudier after the FDA approved Gilead Sciences Inc.'s remdesivir, the first virus treatment to get full authorization in the U.S.

The Food and Drug Administration gave the drug, which is now branded as Veklury, full approval Thursday for patients hospitalized with Covid-19.

The approval marks a major turning point for the U.S. in the fight against Covid-19 and solidifies the standard of care for hospitalized virus patients in the U.S. Shortages of remdesivir—which have been an issue throughout the pandemic—are especially problematic now that it’s been approved because supply issues could slow down development ...